TrialCancer2022

Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.

Naomi Kiyota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.